The role of oxidative stress on necrotizing enterocolitis in very low birth weight infants

Current Pediatric Reviews

Volumn 10, Issue 3, 2014, Pages 202-207

  Perrone, Serafina ^a   Tataranno, Maria Luisa ^a   Santacroce, Antonino ^a   Negro, Simona ^a   Buonocore, Giuseppe ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Antioxidant; Biomarkers; Necrotizing enterocolitis; Oxidative stress; Preterm infants

Indexed keywords

ANTIBIOTIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; CYCLOOXYGENASE 1; CYTOKINE; FREE RADICAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; LIPID HYDROPEROXIDE; MEMBRANE LIPID; NITRIC OXIDE; PEROXYNITRITE; PLATELET ACTIVATOR FACTOR; PROBIOTIC AGENT; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E2; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; STRUCTURAL PROTEIN; SUPEROXIDE; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR 4; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 8-HYDROXYGUANOSINE; ADVANCED OXIDATION PROTEIN PRODUCT; GUANOSINE;

ARTICLE; BIFIDOBACTERIUM LONGUM INFANTIS; CELL DAMAGE; CEREBRAL PALSY; CHILDHOOD MORTALITY; DNA DAMAGE; EARLY DIAGNOSIS; ENTERIC FEEDING; FENTON REACTION; GESTATIONAL AGE; HUMAN; INFANT; INFECTION; INFLAMMATION; ISCHEMIA; LIPID PEROXIDATION; LUNG DYSPLASIA; MEDIATOR RELEASE; MICROCEPHALY; NECROTIZING ENTEROCOLITIS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; OXYGEN TENSION; PATHOPHYSIOLOGY; PERINATAL MORBIDITY; PREMATURITY; PRIORITY JOURNAL; RELIABILITY; REPERFUSION INJURY; RESPIRATORY BURST; RESPIRATORY CHAIN; RETROLENTAL FIBROPLASIA; SHORT BOWEL SYNDROME; STOMACH ACID SECRETION; STOMACH MUCOSA; SURVIVOR; VERY LOW BIRTH WEIGHT; ANALOGS AND DERIVATIVES; BLOOD; ENTEROCOLITIS, NECROTIZING; FETUS BLOOD; INFANT, PREMATURE, DISEASES; METABOLISM; NEWBORN; PROCEDURES;

ADVANCED OXIDATION PROTEIN PRODUCTS; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; ENTERAL NUTRITION; ENTEROCOLITIS, NECROTIZING; FETAL BLOOD; GUANOSINE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; OXIDATIVE STRESS; PROSTAGLANDINS;

EID: 84905569981     PISSN: 15733963     EISSN: 18756336     Source Type: Journal    
DOI: 10.2174/1573396309666140101235126     Document Type: Article

References (71)

1. Holman RC, Stoll BJ, Curns AT, Yorita KL, Steiner CA, Schonberger LB. Necrotising enterocolitis hospitalisations among neonates in the United States. Paediatr Perinat Epidemiol 2006; 20: 498-506.
2. Morgan JA, Young L, McGuire W. Pathogenesis and prevention of necrotizing enterocolitis. Curr Opin Infect Dis 2011; 24(3): 183-9.
3. Boccia D, Stofli I, Lana S, Moro ML. Nosocomial necrotizing enterocolitis outbreaks: Epidemiology and control measures. Eur J Pediatr 2001; 160: 385-91.
4. Lee JH. An update on necrotizing enterocolitis: pathogenesis and preventive strategies. Korean J Pediatr 2011;54(9): 368-72.
5. Milla PJ, Fenton TR. Small intestinal motility patterns in the perinatal period. J Pediatr Gastroenterol Nutr 1983; 2: S141-4.
6. Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr 2011; 159(3): 392-7.
7. Abdelhamid AE, Chuang SL, Hayes P, Fell JM. In vitro cow's milk protein-specific inflammatory and regulatory cytokine responses in preterm infants with necrotizing enterocolitis and sepsis. Pediatr Res 2011; 69(2): 165-9.
8. Moonen RM, Paulussen AD, Souren NY, Kessels AG, Rubio-Gozalbo ME, Villamor E. Carbamoyl phosphate synthetase polymorphisms as a risk factor for necrotizing enterocolitis. Pediatr Res 2007; 62(2): 188-90.
9. Bányász I, Bokodi G, Vásárhelyi B, et al. Genetic polymorphisms for vascular endothelial growth factor in perinatal complications. Eur Cytokine Netw 2006; 17(4): 266-70.
10. Treszl A, Kaposi A, Hajdú J, Szabó M, Tulassay T, Vásárhelyi B. The extent to which genotype information may add to the prediction of disturbed perinatal adaptation: none, minor, or major? Pediatr Res 2007; 62(5): 610-4.
11. Kim M, Christley S, Alverdy JC, Liu D, An G. Immature oxidative stress management as a unifying principle in the pathogenesis of necrotizing enterocolitis: insights from an agent-based model. Surg Infect (Larchmt) 2012; 13(1): 18-32.
12. Nankervis CA, Giannone PJ, Reber KM. The neonatal intestinal vasculature: contributing factors to necrotizing enterocolitis. Semin Perinatol 2008; 32(2): 83-91.
13. Loschen G, Azzi A, Richter C, Flohé L. Superoxide radicals as precursors of mitochondrial hydrogen peroxide. FEBS Lett 1974; 42(1): 68-72.
14. Maréchal A, Mattioli TA, Stuehr DJ, Santolini J. Activation of peroxynitrite by inducible nitric-oxide synthase: a direct source of nitrative stress. J Biol Chem 2007; 11; 282(19): 14101-12.
15. Konturek SJ, Konturek PC, Brzozowski T. Prostaglandins and ulcer healing. J Physiol Pharmacol 2005; 56 Suppl 5: 5-31.
16. Bandyopadhyay D, Chattopadhyay A. Reactive oxygen speciesinduced gastric ulceration: protection by melatonin. Curr Med Chem 2006; 13(10): 1187-202.
17. Gribar SC, Sodhi CP, Richardson WM, et al. Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis. J Immunol 2009; 182: 636-46.
18. Dai S, Sodhi CP, Cetin S, et al. Extracellular high mobility group box1 (HMGB1) inhibits enterocyte migration via activation of toll like receptor 4 and increased cell-matrix adhesiveness. J Biol Chem 2010; 285: 4995-5002.
19. Shindou H, Ishii N, Uozumi T, Shimizu T. Roles of cytosolic phospholipase A2 and platelet activating factor receptor in the Cainduced biosynthesis of PAF. Biochem Biophys Res Commun 2000; 271: 812-7.
20. Svetlov SI, Liu H, Chao W, Olson MS. Regulation of plateletactivating factor (PAF) biosynthesis via coenzyme A-independent transacylase in the macrophage cell line IC-21 stimulated with lipopolysaccharide. Biochim Biophys Acta 1997; 1346: 120-30.
21. Izumi T, Shimizu T. Platelet-activating factor receptor: gene expression and signal transduction. Biochim Biophys Acta 1995; 1259: 317-33.
22. Muguruma K, Gray PW, Tjoelker LW, Johnston JM. The central role of PAF in necrotizing enterocolitis development. Adv Exp Med Biol 1997; 407: 379-82.
23. Amer MD, Hedlund E, Rochester J, Caplan MS. Platelet-activating factor concentration in the stool of human newborns: effects of enteral feeding and neonatal necrotizing enterocolitis. Biol Neonate 2004; 85:159-66.
24. Caplan MS, Hedlund E, Adler L, Lickerman M, Hsueh W. The platelet activating factor receptor antagonist WEB 2170 prevents neonatal necrotizing enterocolitis in rats. J Pediatr Gastroenterol Nutr 1997; 24: 296-301.
25. Caplan MS, Lickerman M, Adler L, Dietsch GN, Yu A. The role of recombinant platelet activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis. Pediatr Res 1997; 42: 779-83.
26. Jilling T, Simon D, Lu J et al. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol 2006; 177: 3273-82.
27. Owens L, Berseth CL. Is there a volume threshold for enteral feeding and necrotizing enterocolitis? Pediatr Res 1995; 37: 315A.
28. Berseth CL, Bisquera JA, Paje VU. Prolonging small feeding volumes early in life decreases the incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2003; 111: 529-34.
29. Lucas A, Cole TJ. Breast milk and neonatal necrotizing enterocolitis. Lancet 1990; 336: 1519-23.
30. Caplan MS, Miller-Catchpole R, Kaup S et al. Bifidobacterial supplementation reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Gastroenterology 1999; 117: 577-83.
31. Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotizing enterocolitis in preterm neonates with very low birth weight: a systematic review of randomized controlled trials. Lancet 2007; 369: 1614-20.
32. Kosloske AM. Epidemiology of necrotizing enterocolitis. Acta Paediatr Suppl 1994; 396: 2-7.
33. Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: pathogenesis, prevention and management. Drugs 2008; 68(9): 1227-38.
34. Schnabl KL, Van Aerde JE, Thomson AB, Clandinin MT. Necrotizing enterocolitis: a multifactorial disease with no cure. World J Gastroenterol 2008; 14(14): 2142-61.
35. Leviton A, Dammann O, Engelke S, et al. The clustering of disorders in infants born before the 28th week of gestation. Acta Paediatr 2010; 99: 1795-1800.
36. Rees CM, Pierro A, Eaton S. Neurodevelopmental outcomes of neonates with medically and surgically treated necrotizing enterocolitis. Arch Dis Child Fetal Neonatal Ed 2007; 92: F193-F198.
37. Martin CR, Dammann O, Allred EN, et al. Neurodevelopment of extremely preterm infants who had necrotizing enterocolitis with or without late bacteremia. J Pediatr 2010; 157: 751-6.
38. Duro D, Kalish LA, Johnston P, et al. Risk factors for intestinal failure in infants with necrotizing enterocolitis: a Glaser Pediatric Research Network study. J Pediatr 2010; 157: 203-8201.
39. Stanford A, Upperman JS, Boyle P, Schall L, Ojimba JI, Ford HR. Long-term follow-up of patients with necrotizing enterocolitis. J Pediatr Surg 2002; 37(7): 1048-50.
40. Buonocore G, Groenendaal F. Anti-oxidant strategies. Semin Fetal Neonatal Med 2007; 12: 287-95.
41. Buonocore G, Perrone S, Tataranno ML. Oxygen toxicity: chemistry and biology of reactive oxygen species. Semin Fetal Neonatal Med 2010; 15: 186-90.
42. Bonassi S, Au WW. Biomarkers in molecular epidemiology studies for health risk prediction. Mutat Res 2002; 511: 73-86.
43. Ogino K, Wang DH. Biomarkers of oxidative/nitrosative stress: an approach to disease prevention. Acta Med Okayama 2007; 61: 181-9.
44. Halliwell B. The wanderings of a free radical. Free Radic Biol Med 2009; 46: 531-542.
45. Morrow J, Roberts L. The isoprostanes. Current knowledge and directions for future research. Biochem. Pharmacol 1996; 12: 1-9.
46. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28(4): 505-13.
47. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International 1996; 49: 1304-13.
48. Perrone S, Tataranno ML, Negro S, et al. May oxidative stress biomarkers in cord blood predict the occurrence of necrotizing entero colitis in preterm infants? J Matern Fetal Neonatal Med 2012; 25S1: 128-31.
49. Alderman CJ, Shah S, Foreman JC, Chain BM, Katz DR. The role of advanced oxidation protein products in regulation of dendritic cell function. Free Radic Biol Med 2002; 32: 377-85.
50. Buonocore G, Perrone S, Longini M, Terzuoli L, Bracci R. Total hydro peroxide and advanced oxidation protein products in preterm hypoxic babies. Pediatr Res 2000; 47: 221-4.
51. Buonocore G, Perrone S, Longini M, et al. Oxidative stress in preterm neonates at birth and on the seventh day of life. Pediatr Res 2002; 52: 46-9.
52. Papanikolau G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005; 202: 199-211.
53. Buonocore G, Zani S, Perrone S, Caciotti B, Bracci R. Intra erythrocyte non protein-bound iron and plasma malondialdehyde in the hypoxic newborn. Free Radic Biol Med 1998; 25: 766-70.
54. Buonocore G, Zani S, Sargentini I, Gioia D, Signorini C, Bracci R. Hypoxia induced free iron release in the red cells of newborn infants. Acta Paediatr 1998; 87: 77-81.
55. Paffetti P, Perrone S, Longini M, et al. Non-protein-bound iron detection in small samples of biological fluids and tissue. Biol Trace Elem Res 2006; 112: 221-232.
56. Buonocore G, Perrone S, Longini M, Paffetti P, Gatti MG, Bracci R. Non protein bound iron as predictive marker of neonatal brain damage. Brain 2003; 126: 1-7.
57. Young C, Sharma R, Handfield M, Mai V, Neu J. Biomarkers for infants at risk for necrotizing enterocolitis: clues to prevention? Pediatr Res 2009; 65(5 Pt 2): 91R-97R.
58. Perrone S, Tataranno ML, Negro S, et al. Early identification of the risk for free radical-related diseases in preterm newborns. Early Hum Dev 2010; 86(4): 241-4.
59. Perrone S, Vezzosi P, Longini M, et al. Biomarkers of oxidative stress in babies at high risk for retinopathy of prematurity. Front Biosci (Elite Ed) 2009; 1: 547-52.
60. Ozdemir R, Yurttutan S, Sari FN, et al. All-trans-retinoic acid attenuates intestinal injury in a neonatal rat model of necrotizing enterocolitis. Neonatology 2013;104(1): 22-7.
61. Rao J, Qian X, Wang P, et al. All-trans retinoic acid preconditioning protects against liver ischemia/reperfusion injury by inhibiting the nuclear factor kappa B signaling pathway. J Surg Res 2013; 180(2): e99-e106.
62. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short-and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2011; (10): CD000501.
63. Weinberg ED. Human lactoferrin: a novel therapeutic with broad spectrum potential. J Farm Farmacol 2001; 53: 1303-10.
64. Leibman A, Aisen P. Distribution of iron between the binding sites of transferrin in serum: methods and results in normal human subjects. Blood 1979; 53(6): 1058-65.
65. Bullen JJ, Rogers HJ, Leigh L. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. Br Med J 1972; 1(5792): 69-75.
66. Sanchez L, Calvo M, Brock J H. Biological role of lactoferrin. Arch Dis Child 1992; 67: 657-61.
67. Baldwin DA, Jenny ER, Aisen P. The effect of human serum transferrin and milk lactoferrin on hydroxyl radical formation from superoxide and hydrogen peroxide. J Biol Chem 1984; 259: 13391-4.
68. Weinberg ED. The therapeutic potential of lactoferrin. Expert Opin Investig Drugs 2003; 12: 841-51.
69. Lönnerdal B. Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr 2003; 77: 1537S-43S.
70. Manzoni P, Rinaldi M, Cattani S, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birthweight neonates: a randomized trial. JAMA 2009; 302: 1421-8.
71. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011; (10): CD007137.